Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA–PABA–MAC and 5-ASA–PABA–Diamine for the Treatment of Ulcerative Colitis

Jiaxing Zhao,Bing Zhang,Qing Mao,Kunqi Ping,Peng Zhang,Fengwei Lin,Dan Liu,Yao Feng,Ming Sun,Yan Zhang,Qiu Hua Li,Tingjian Zhang,Yanhua Mou,Shaojie Wang

DOI: https://doi.org/10.1021/acs.jmedchem.1c02166

IF: 8.039

2022-03-11

Journal of Medicinal Chemistry

Abstract:To mitigate the systemic adverse effects of tofacitinib, 5-ASA–PABA–MAC and 5-ASA–PABA–diamine colon-specific delivery systems were constructed, and tofacitinib azo prodrugs 9 and 20a–20g were synthesized accordingly. The release studies suggested that these systems could effectively release tofacitinib in vitro, and the 5-ASA–PABA–diamine system could successfully realize the colon targeting of tofacitinib in vivo. Specifically, compound 20g displayed a 3.67-fold decrease of plasma AUC(tofacitinib, 0–∞) and a 9.61-fold increase of colonic AUC(tofacitinib, 0–12h), compared with tofacitinib at a molar equivalent oral dose. Moreover, mouse models suggested that compound 20g (1.5 mg/kg) could achieve roughly the same efficacy against ulcerative colitis compared with tofacitinib (10 mg/kg) and did not impair natural killer cells. These results demonstrated the feasibility of compound 20g as an effective alternative to mitigate the systemic adverse effects of tofacitinib, and 5-ASA–PABA–MAC and 5-ASA–PABA–diamine systems were proven to be effective for colon-specific drug delivery.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c02166.Spectral characterization data for all of the key intermediates and final compounds (PDF)Molecular formula strings (CSV)This article has not yet been cited by other publications.

chemistry, medicinal